nanotech-investing Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
nanotech-investing Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
